Publication date: Feb 18, 2025
The study aimed to assess the effect of COVID-19 on hepatic lipid (HL) content, fibrosis risk, and adiposity in persons with type 2 diabetes. Participants with type 2 diabetes with a history of mild COVID-19 (n=15, age 58+/-12 years, body mass index 30. 9+/-5. 2 kg/m) were examined before (baseline) and 1 year (12+/-2 months) after (follow-up) recovery from COVID-19. Investigations for changes in metabolic risk comprised clinical examination, fasting blood sampling and MR-based measurements. Potential changes were corrected with the time course of the respective parameters in a group of participants who did not contract COVID-19 over the same time course (n=14, 61+/-6 years, 30. 0+/-4. 6 kg/m). COVID-19 resulted in a relative increase in HL content of 56% (95% CI 18%, 106%; p=0. 04) measured as proton density fat fraction (HL-PDFF), corrected for the time course in the absence of COVID-19. While no changes in hepatic stiffness and volume, intramyocellular lipids, whole-body, subcutaneous and visceral adipose tissue volumes as well as homeostatic model assessment of insulin resistance and beta-cell function were observed. History of COVID-19 in persons with type 2 diabetes is associated with higher HL-PDFF after 1 year following recovery from infection. NCT01055093.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | type 2 diabetes |
| disease | MESH | fibrosis |
| disease | IDO | history |
| disease | IDO | blood |
| disease | MESH | insulin resistance |
| pathway | KEGG | Insulin resistance |
| disease | IDO | cell |
| disease | MESH | infection |
| disease | MESH | Long Covid |